1. Introduction {#sec0001}
===============

A myriad of publications addressing COVID-19 and its impact on acute and chronic neurological disorders have been published in the last few months. Special interest has arisen in chronic demyelinating disorders, such as Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorders (NMOSD), mainly due to immunotherapy and increased risk of infections ([@bib0001]). In MS, a multicentric study led by the Italian program for COVID-19 infection in multiple sclerosis, including 238 symptomatic patients (57 had positive RT-PCR) from 38 centers, seems to reassure that most patients (96%) developed a mild disease. Unfortunately, 5 patients died, all of them with EDSS ≥ 6.5^2^. An observational study including 8 patients from North America, also highlights the importance of EDSS in the risk of fatal outcome ([@bib0003]). A more recent multicentric study, including 347 patients from the Covisep French registry, showed that 21% of the patients at least required hospitalization, while 12 patients (3.5%) died. Multivariate analyses determined that EDSS, age and obesity were independent risk factors for hospitalization or more severe COVID-19, while no association between disease-modifying therapy exposure and COVID-19 severity was observed ([@bib0004]). In NMOSD fewer articles have been published, also suggesting a similar rate of infection compared to the general population ([@bib0005]).

On May 16th, our group published a first report addressing the impact of COVID-19 using an online survey completed by 280 patients, highlighting the relevance of early communication for infection prevention measures, and social impact of telemedicine and remote-working. Main results included a high percentage of patients under disease-modifying therapy (95%), a high percentage of patients reporting at least one comorbidity (60%), 75% stated to be remote working/studying since early March, and 8% declared to be unemployed. Three patients were confirmed with COVID-19, with no fatal outcomes ([@bib0006]). Unfortunately, over 100 days after the first patient was confirmed in Chile, things have dramatically changed. The number of cases and deaths due to COVID-19 has exponentially increased, with over 300,000 patients diagnosed (1.6% of the total population) and over 6500 deaths (2.2%) ([@bib0007]). Therefore, a second online questionnaire was distributed among MS and NMOSD treating neurologists throughout the country in order to assess a national representation of the impact of COVID-19 in their patients' lives, and to improve and update the recommendations given to patients and caregivers, in the event of a confirmed infection. Patients under regular clinical care had already given written informed consent approved by the local Ethics Committee. Also, before survey completion, patients were asked to agree on an online informed consent. A total of 409 surveys from 9 centers have been completed, 71% women, mean age 41 years, 98% with MS, and 88% receiving immunotherapy. Most prevalent self-reported comorbidities were being overweight/obese (17%), current smoking (14%), insulin resistance/type 2 diabetes (9%), thyroid disorders (8%) and hypertension (8%). Remote working-studying remains high (74%), but unemployment has risen to 10%. Compared to our previous study, a similar proportion of patients (16%) reported having any symptom suggestive of COVID-19 ([Table 1](#tbl0001){ref-type="table"} ). Eighteen patients have been diagnosed with COVID-19 (14 RRMS, 4 NMOSD), 12 women (67%), median age of 32.5 years (range 17--61), median disease duration of 7 years (range 0.3--12) and median EDSS of 1.0 (0--6.0). No progressive MS patient has yet been infected. All patients had at least one comorbidity, and all were receiving immunotherapy. No changes in disease-modifying therapy were suggested in 11 patients, while 6 patients required transient suspension, and one patient required stress dose steroids. Five patients (28%, 3/5 men) required hospitalization, while one patient (NMOSD, male, EDSS 6.0, with hypertension and type 2 diabetes), required invasive mechanical ventilation, and had a fatal outcome due to critical illness polyneuromyopathy and secondary bacterial infection ([Table 2](#tbl0002){ref-type="table"} ).Table 1Characteristics of surveyed patients *N* = 409.Table 1DemographicDisease-relatedSex N(%) female: male290 (71):118(29)DiagnosisN (%)Age mean+SD (range)41.2 + 11.4(17--81)MS400(98)Health Insurance N(%) public:private:other77(19)/325(79)/7(2)NMOSD5(1)Current pregnancy N(%)3(1)Other4(1)Current treatmentN (%)Self-reported comorbiditiesN (%)Any DMT360(88)Overweight/obese70(17)Interferon beta47(11)Current smoking57(14)Glatiramer acetate16(4)Insulin resistance/type 2 diabetes36(9)Teriflunomide20(5)Thyroid disorder32(8)Dimethyl fumarate17(4)Hypertension32(8)Fingolimod118(29)Other autoimmune disease36(9)Cladribine17(4)Dyslipidemia25(6)Natalizumab12(3)Asthma/COPD20(5)Ocrelizumab77(19)Mood disorder5(1)Rituximab16(4)Cancer4(1)Alemtuzumab17(4)Cardiac disease3(1)Azathioprine1(0)Epilepsy3(1)Mycophenolate2(1)Another comorbidity12(3)No immunotherapy49(12)No comorbidity159(39)Social InformationN (%)COVID-19N (%)Medical leave due to MS12(3)Any symptom suggestive of COVID-1965(16)Medical leave du to other diagnosis16(4)Headache35(54)Unemployed41(10)Sore throat33(52)Homesteader/Home keeper42(10)Cough28(44)Full-time student11(3)Malaise26(40)Part-time student1(0)Diarrhea21(33)Retired due to MS33(8)Fever12(19)Retired due to age8(2)Dyspnea11(17)Full-time job200(49)Anosmia6(9)Part-time job45(11)Nasal congestion2(3)Remote working/studying303(74)Eye infection1(2)In-office working/studying45(11)Measures taken after symptom onsetMixed remote and in-office61(15)Stayed at home42(65)Visited Emergency Room6(9)Consulted treating neurologist8(13)Consulted another doctor9(14)COVID-19 test14(22)Required hospitalization5(8)[^1]Table 2Characteristics of patients with confirmed or suspected COVID-19 and MS or NMOSD.Table 2PatientRT-PCRSexAge (years)DiagnosisDisease Duration (years)EDSSComorbiditiesDMTDMT modification or interruptionHospitalizationIMVCOVID-19 symptoms and Follow-upOutcome1positivemale30RRMS61insulin resistance, hypothyroidismocrelizumabno change - last infusion 10 days before symptoms onsetyesnobilateral pneumonia, readmission due to Adenovirus pneumoniafull recovery2positivefemale23RRMS81insulin resistancedimethyl fumaratesuspended for 35 days until clinical recoveryyesnobilateral pneumoniafull recovery3positivefemale24RRMS91migraine, depression, insulin resistancefingolimodsuspended for 21 days until clinical recoveryyesnomyalgias and feverfull recovery4positivemale61NMOSD-AQP40.36hypertension, type 2 diabetesprednisonesteroid stress doseyesyesbilateral pneumonia, tracheostomyfatal5positivefemale54NMOSD-AQP4123insulin resistance, pernicious anemia, osteoarthritismycophenolateno changenonoanosmiafull recovery6positivefemale29RRMS71hypothyroidismfingolimodsuspended for 5 days until clinical recoverynonomyalgias and feverfull recovery7not performed - close contact with positive PCR, positive IgMfemale23RRMS2.51obesitydimethyl fumarateno changenonomyalgias and feverfull recovery8positivemale55RRMS71depressionteriflunomidesuspended for 7 days until clinical recoverynonomyalgias and fever, recovering at homefull recovery9positivefemale57RRMS74anxiety, type 2 diabetesfingolimodno changenonosore throat, headache, mild dyspneafull recovery10positivemale17RRMS20asthmafingolimodno changenonoasymptomaticfull recovery11not performed - close contact with positive PCRfemale28NMOSD32.5obesitymycophenolateno changenonoanosmia, fever and diarrheafull recovery12not performed - close contact with positive PCR, positive IgGfemale44RRMS63depression, cutaneous amyloidosisnatalizumablast dose 4 months prior infection - waiting for switching to cladribinenonoanosmia, diarrhea, feverfull recovery13positivemale40NMOSD-MOG0.62.5depressionazathioprinesuspension for 1 monthyesnomyalgia, fever and sore throat, dyspnea, suspected bacterial sobreinfection, received tocilizumabfull recovery14positivefemale52RRMS81depression, obesity, hypertension, insulin resistanceteriflunomideno changenonodry coughfull recovery15positivefemale31RRMS32hypothyroidismfingolimodno changenonoasymptomaticfull recovery16positive, IgG positivefemale34RRMS71secondary thyroiditisalemtuzumabno change - last dose October 2018nonomyalgia, headache, anosmiarecovering at home17positivemale36RRMS42migraine, depressioninterferon beta 1a IMno changenonomyalgia, rhinorrhea, anosmiarecovering at home18not performed, negative IgGfemale31RRMS141migrainealemtuzumab 4 doses, ocrelizumabno change - last infusion 2 months before symptom onsetnonofever, myalgia, headache, anosmiarecovering at home[^2]

The sustained worsening of the COVID-19 pandemic in our country warrants an urgent need in maintaining fluid communication with our patients. Although this is a small study in a country with an estimated prevalence of 13.4 per 100,000 habitants ([@bib0008]), we achieved a representative 16% of the estimated total MS population of 2546 patients. We noticed a possible impact of comorbidities, age, male gender and higher EDSS in the outcome of COVID-19 severe acute respiratory syndrome, with no clear relationship with any specific disease-modifying therapy. Nonetheless, the small sample size of this case series is a major limitation for further conclusions. Results from large multicentric databases such as the Italian ([@bib0002]) and French ([@bib0004]) registries will better elucidate the real influence of these variables on COVID-19 outcomes.

The results from this survey has also impacted our clinical practice and we have changed the way our MS program works. We have implemented telemedicine consultations in over 80% of our routine or emergent visits, infusions have been postponed and rescheduled to an outpatient clinic infusion center, physical therapy, neurocognitive rehabilitation and psychological support access have decreased and efforts are being made in order to maintain the standard clinical care for our MS-NMOSD community.

Maintaining the connection between the different MS groups at national and international levels will be essential to delineate future directions regarding the changes that COVID-19 is generating in the care of our patients.
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[^1]: DMT disease-modifying therapy, MS multiple sclerosis, NMOSD Neuromyelitis Optica Spectrum Disorders, COPD chronic obstructive pulmonary disease.

[^2]: RT-PCR: real-time polymerase chain reaction; RRMS relapsing-remitting multiple sclerosis; NMOSD Neuromyelitis Optica Spectrum Disorder; AQP4 aquaporin 4; MOG myelin oligodendrocyte glycoprotein; EDSS expanded disability status scale, DMT disease modifying therapy, IMV invasive mechanical ventilation.
